BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Aug 4, 2016
Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Glutathione S-transferase π 1 (GSTP1); cereblon (CRBN)

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture, in vitro and patient sample studies identified a promoter of CRBN-mediated GSTP1 degradation that could help treat AML. Screening of thalidomide analogs in human AML cell lines...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Glutathione S-transferase pi 1 (GSTP1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting GSTP1 could help treat triple-negative breast cancer (TNBC). Levels of GSTP1 were higher in TNBC cell lines and TNBC tumor samples from...
BioCentury | Aug 4, 2014
Emerging Company Profile

Myelo: Preventing neutropenia

Myelo Therapeutics GmbH is developing a small molecule that could provide a cheaper and safer alternative to standard of care G-CSF to prevent and to treat chemotherapy-induced neutropenia. Neutropenia is a decrease in levels of...
BioCentury | May 19, 2014
Company News

MabVax, Telik deal

The cancer companies will merge in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik shareholders will own 15% of the combined company, and MabVax shareholders will own the...
BioCentury | Aug 29, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Low-density lipoprotein-related protein 1 a-2-macroglobulin receptor (LRP1; CD91); neurotrophic tyrosine kinase receptor 3 (NTRK3; TrkC) Cell culture and rat...
BioCentury | Apr 15, 2013
Company News

Oncor, The Johns Hopkins University deal

Oncor licensed a patent from the university for genetic diagnosis of prostate cancer. The company said the technology demonstrated that loss of expression of the glutathione-S-transferase gene (GSTP1) predicts development of prostate cancer. GSTP1 expression...
BioCentury | Apr 15, 2013
Company News

Terrapin, Taiho deal

The companies entered into a definitive agreement to advance the development of Terrapin's TER286 broad spectrum cancer compound. Taiho will provide R&D funding and Terrapin will be responsible for preclinical testing and preparation for an...
Items per page:
1 - 10 of 140